• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Cosette Pharmaceuticals Appoints Vincent Colicchio as Senior Vice President of Operations

    2/10/25 8:00:00 AM ET
    $HLNE
    Investment Managers
    Finance
    Get the next $HLNE alert in real time by email

    Industry leader with 35+ years of experience in manufacturing operations and global supply chain excellence

    Cosette Pharmaceuticals, Inc., a leading specialty pharmaceuticals company, today announced the appointment of Vincent (Vin) Colicchio as Senior Vice President of Operations, effective February 3, 2025. In this role, Vin will lead Cosette's manufacturing, global supply chain, and operational strategy, ensuring efficiency, and supply continuity as the company continues its strong trajectory of growth and transformation.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210366017/en/

    Senior Vice President, Operations (Photo: Business Wire)

    Senior Vice President, Operations (Photo: Business Wire)

    "As we rapidly diversify our product portfolio and expand our footprint, we continue to enhance our operational capabilities" said Apurva Saraf, President and CEO, Cosette Pharmaceuticals. "Vin is an exceptional leader with deep expertise in leading complex operations with high-performing teams and driving efficiencies. His experience at large-scale U.S. manufacturing and global supply chain operations will play a critical role as we continue to advance our capabilities and expand our portfolio."

    Vin brings more than 35+ years of leadership in pharmaceutical manufacturing and supply chain operations, spanning semi-solids, liquids, oral solids, and transdermals in both branded and generic markets. Most recently, he served as Vice President of Supply Chain and External Manufacturing at Dr. Reddy's Laboratories, where he led end-to-end supply chain operations for North America, overseeing a network of more than 45 CMOs and CPOs across the US, Canada, and Europe. He played a key role in the acquisition and integration of Mayne Pharma's generics portfolio, strengthening Dr. Reddy's market position and operational efficiency.

    Prior to Dr. Reddy's, Vin held senior leadership roles at Amneal Pharmaceuticals, G&W Laboratories, GlaxoSmithKline, UCB Pharma, and Wyeth, where he successfully led manufacturing expansions, supply chain transformations, and operational optimization initiatives. His ability to streamline production, enhance supply resilience, and drive best-in-class manufacturing excellence has made him a recognized leader in the industry.

    "Cosette's dynamic growth and commitment to operational excellence make this an incredibly exciting opportunity," said Vin Colicchio, Senior Vice President, Operations. "I look forward to working alongside the talented teams at Cosette to scale our manufacturing capabilities, enhance supply chain agility, and to ensure seamless delivery of the highest quality medicines to the patients."

    Vin holds a B.S. in Biochemical Engineering from Rutgers University and an MBA in Management.

    About Cosette Pharmaceuticals:

    Cosette Pharmaceuticals, Inc. ("Cosette") is a US-based, fully integrated pharmaceutical company with a fast-growing portfolio of branded pharmaceuticals consisting of products in women's health, cardiology and dermatology. Cosette has a long history in quality manufacturing of complex dosage forms including topical creams, ointments, oral liquids/solutions and suppositories. Cosette has corporate and manufacturing facilities in New Jersey and North Carolina and is supported by 350+ dedicated team members across all functional areas. Cosette is backed by Avista Healthcare Partners, a healthcare focused private equity firm, and funds managed by Hamilton Lane, a private markets investment management firm (NASDAQ:HLNE). For more information, please visit www.cosettepharma.com and follow us on LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250210366017/en/

    [email protected]

    Get the next $HLNE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HLNE

    DatePrice TargetRatingAnalyst
    5/15/2025Outperform → Perform
    Oppenheimer
    1/21/2025$186.00Perform → Outperform
    Oppenheimer
    1/6/2025$139.00Neutral → Sell
    Goldman
    9/12/2024$156.00Equal Weight
    Wells Fargo
    4/11/2024$115.00Overweight → Neutral
    JP Morgan
    1/11/2024Outperform → Perform
    Oppenheimer
    5/26/2023$87.00Perform → Outperform
    Oppenheimer
    3/15/2023$85.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $HLNE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PennantPark Floating Rate Capital Ltd. Announces New Investment Venture with Hamilton Lane

    MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (the "Company") (NYSE:PFLT) today announced that it has formed PennantPark Senior Secured Loan Fund II, LLC ("PSSL II"), a joint venture with a fund managed by Hamilton Lane (NASDAQ:HLNE) ("HL"). PSSL II is expected to invest primarily in middle market loans consistent with PFLT's core origination and underwriting strategy. PFLT and HL have committed to provide a combined $200 million of notes and equity to the joint venture, with PFLT providing $150 million and HL providing $50 million. PSSL II intends to add a financing facility of $300 million which will enable the portfolio to grow to $500 million initiall

    8/11/25 4:05:00 PM ET
    $HLNE
    $PFLT
    Investment Managers
    Finance
    Finance: Consumer Services

    HAMILTON LANE INCORPORATED REPORTS FIRST QUARTER FISCAL 2026 RESULTS

    CONSHOHOCKEN, Pa., Aug. 5, 2025 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the first fiscal quarter ended June 30, 2025. The Company issued a full detailed presentation of its first quarter fiscal 2026 results, which can be accessed on the Company's Shareholders website at https://shareholders.hamiltonlane.com/ Dividend Hamilton Lane has declared a quarterly dividend of $0.54 per share of Class A common stock to record holders at the close of business on September 19, 2025 that will be paid on October 6, 2025. The target full-year dividend of $2.16 represents a 10% increase from the prior fiscal year

    8/5/25 7:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Wormhole Powers Multichain Interoperability of Tokenized Access Fund for Hamilton Lane's SCOPE Fund with Securitize

    Wormhole selected as official multichain partner for accessing $958B1 private markets investment manager's senior credit fund through the Senior Credit Opportunities Securitize Fund (SCOPE Access Fund), now live on Ethereum and Optimism via Securitize. GRAND CAYMAN, Cayman Islands, July 17, 2025 /PRNewswire/ -- Wormhole, a leading interoperability platform connecting traditional finance and the internet economy, has been selected as the official interoperability partner for SCOPE Access Fund, a tokenized feeder fund offering exposure to Hamilton Lane's Senior Credit Opportunities Fund (SCOPE), through its partnership with Securitize, a leading tokenized asset platform. Originally launched i

    7/17/25 11:20:00 AM ET
    $HLNE
    Investment Managers
    Finance

    $HLNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider French River 5 Ltd claimed ownership of 480,015 shares and claimed ownership of 7 units of Class B Common Stock (SEC Form 3)

    3 - Hamilton Lane INC (0001433642) (Issuer)

    4/25/25 5:05:37 PM ET
    $HLNE
    Investment Managers
    Finance

    Co-Chief Executive Officer Delgado-Moreira Juan was granted 34,031 shares, increasing direct ownership by 3% to 1,298,847 units (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    3/18/25 5:00:47 PM ET
    $HLNE
    Investment Managers
    Finance

    Co-Chief Executive Officer Hirsch Erik R. was granted 36,001 shares and covered exercise/tax liability with 3,386 shares, increasing direct ownership by 37% to 120,275 units (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    3/18/25 4:58:27 PM ET
    $HLNE
    Investment Managers
    Finance

    $HLNE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Delgado-Moreira Juan bought $105,950 worth of shares (525 units at $201.81) (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    11/13/24 4:31:06 PM ET
    $HLNE
    Investment Managers
    Finance

    $HLNE
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Hamilton Lane Incorporated

    SCHEDULE 13G - Hamilton Lane INC (0001433642) (Subject)

    8/13/25 4:05:09 PM ET
    $HLNE
    Investment Managers
    Finance

    SEC Form 10-Q filed by Hamilton Lane Incorporated

    10-Q - Hamilton Lane INC (0001433642) (Filer)

    8/5/25 4:15:18 PM ET
    $HLNE
    Investment Managers
    Finance

    Hamilton Lane Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Hamilton Lane INC (0001433642) (Filer)

    8/5/25 7:00:01 AM ET
    $HLNE
    Investment Managers
    Finance

    $HLNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hamilton Lane downgraded by Oppenheimer

    Oppenheimer downgraded Hamilton Lane from Outperform to Perform

    5/15/25 8:08:14 AM ET
    $HLNE
    Investment Managers
    Finance

    Hamilton Lane upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Hamilton Lane from Perform to Outperform and set a new price target of $186.00

    1/21/25 7:49:57 AM ET
    $HLNE
    Investment Managers
    Finance

    Hamilton Lane downgraded by Goldman with a new price target

    Goldman downgraded Hamilton Lane from Neutral to Sell and set a new price target of $139.00

    1/6/25 8:11:18 AM ET
    $HLNE
    Investment Managers
    Finance

    $HLNE
    Leadership Updates

    Live Leadership Updates

    View All

    Cosette Pharmaceuticals Appoints Jeff Neubig as Vice President, Quality and Regulatory Affairs

    -- Experienced Industry Leader to drive Cosette's Best-in-Class Quality Organization and facilitate Regulatory Approvals -- Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has appointed Jeff Neubig as Vice President, Quality and Regulatory Affairs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630266171/en/Jeff Neubig, VP, Quality & Regulatory Affairs, Cosette Pharmaceuticals In this critical role, Jeff will lead Cosette's best-in-class quality and regulatory affairs organizations, maintaining the company's rigorous quality standards and further establishing Co

    6/30/25 8:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Grenova Secures New Investment; Appoints Life Sciences Veteran to the Board

    Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova's board, and the successful completion of a new round of growth equity capital. These developments support Grenova's strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories worldwide. Ted Hull brings over 30 years of experience in the life sciences industry, including as a clinical lab CEO for the last 20+ years. In his role at Grenova, Mr. Hull is set to provide strategic leadership and to play a pivotal role in shaping the company's future. "I

    4/23/25 8:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Cosette Pharmaceuticals Appoints Vincent Colicchio as Senior Vice President of Operations

    Industry leader with 35+ years of experience in manufacturing operations and global supply chain excellence Cosette Pharmaceuticals, Inc., a leading specialty pharmaceuticals company, today announced the appointment of Vincent (Vin) Colicchio as Senior Vice President of Operations, effective February 3, 2025. In this role, Vin will lead Cosette's manufacturing, global supply chain, and operational strategy, ensuring efficiency, and supply continuity as the company continues its strong trajectory of growth and transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210366017/en/Senior Vice President, Operations (Photo

    2/10/25 8:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    $HLNE
    Financials

    Live finance-specific insights

    View All

    HAMILTON LANE INCORPORATED REPORTS FIRST QUARTER FISCAL 2026 RESULTS

    CONSHOHOCKEN, Pa., Aug. 5, 2025 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the first fiscal quarter ended June 30, 2025. The Company issued a full detailed presentation of its first quarter fiscal 2026 results, which can be accessed on the Company's Shareholders website at https://shareholders.hamiltonlane.com/ Dividend Hamilton Lane has declared a quarterly dividend of $0.54 per share of Class A common stock to record holders at the close of business on September 19, 2025 that will be paid on October 6, 2025. The target full-year dividend of $2.16 represents a 10% increase from the prior fiscal year

    8/5/25 7:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Hamilton Lane Incorporated to Announce First Quarter Fiscal 2026 Results on August 5, 2025

    CONSHOHOCKEN, Pa., July 15, 2025 /PRNewswire/ -- Hamilton Lane Incorporated (NASDAQ:HLNE) is scheduled to release financial results for the first fiscal quarter ended June 30, 2025 before the market opens on Tuesday, August 5, 2025. A copy of the earnings release and full detailed presentation will be available on the Hamilton Lane Shareholders website at https://shareholders.hamiltonlane.com/. Hamilton Lane will host a conference call via webcast at 11:00 a.m. ET on August 5 to discuss the results for the first fiscal quarter. For access to the live event via the webcast, visit Hamilton Lane's Shareholder's website by clicking here (https://shareholders.hamiltonlane.com/) at least 15 minut

    7/15/25 7:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    HAMILTON LANE INCORPORATED REPORTS STRONG FOURTH FISCAL QUARTER AND FISCAL YEAR 2025 RESULTS, WITH MANAGEMENT AND ADVISORY FEES GROWING BY 14% AND ASSETS UNDER MANAGEMENT GROWING BY 11% YEAR-OVER-YEAR

    CONSHOHOCKEN, Pa., May 29, 2025 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the fourth fiscal quarter and full fiscal year ended March 31, 2025. FISCAL YEAR 2025 HIGHLIGHTS Assets under management – Total assets under management of $138 billion grew 11% year-over-year. Fee-earning assets under management increased 10% to $72 billion over the same period.Revenue – Management and advisory fees increased 14% to $513.9 million for fiscal 2025.Carried Interest – Unrealized carried interest balance of $1.3 billion was up 3% year-over-year.Earnings per share – GAAP EPS of $5.41 on $217.4 million of GAAP net i

    5/29/25 7:08:00 AM ET
    $HLNE
    Investment Managers
    Finance

    $HLNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hamilton Lane Incorporated

    SC 13G/A - Hamilton Lane INC (0001433642) (Subject)

    11/13/24 9:56:40 PM ET
    $HLNE
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by Hamilton Lane Incorporated

    SC 13G/A - Hamilton Lane INC (0001433642) (Subject)

    11/12/24 3:55:46 PM ET
    $HLNE
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by Hamilton Lane Incorporated

    SC 13G/A - Hamilton Lane INC (0001433642) (Subject)

    11/4/24 11:53:29 AM ET
    $HLNE
    Investment Managers
    Finance